{"date":"2026-08-25","count":18,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6748-2026-08-25-2009-bbl6dq","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2026-08-25","time":"20:09:22","subject":"公告本公司與星誠細胞生醫簽訂合作意向書","clause":"第8款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2026-08-25 20:09，「公告本公司與星誠細胞生醫簽訂合作意向書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-08-25-1812-17k90kf","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-08-25","time":"18:12:21","subject":"代子公司欣安健康事業(股)公司公告股東臨時會決議減資","clause":"第11款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-08-25 18:12，「代子公司欣安健康事業(股)公司公告股東臨時會決議減資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-08-25-1811-ip7qxj","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-08-25","time":"18:11:45","subject":"代子公司欣安健康事業(股)公司公告股東臨時會決議不分配股利","clause":"第14款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-08-25 18:11，「代子公司欣安健康事業(股)公司公告股東臨時會決議不分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7799-2026-08-25-1805-azikff","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2026-08-25","time":"18:05:21","subject":"本公司研發之B10 L-BPA 注射液第一及第二期復發型腦膜瘤學術研究用人體臨床試驗，具安全性和有效性","clause":"第10款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2026-08-25 18:05，「本公司研發之B10 L-BPA 注射液第一及第二期復發型腦膜瘤學術研究用人體臨床試驗，具安全性和有效性」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6844-2026-08-25-1801-1bi2fou","company_id":"6844","company":"諾貝兒","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"18:01:51","subject":"本公司受邀參加台新證券舉辦之法人說明會","clause":"第12款","fact_date":"2026-08-26","cite_as":"公開資訊觀測站重大訊息：諾貝兒（6844），2026-08-25 18:01，「本公司受邀參加台新證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2026-08-25-1750-19yrxsh","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"17:50:48","subject":"代重要子公司Medic Vision AI Limited公告股東會召開事宜","clause":"第17款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2026-08-25 17:50，「代重要子公司Medic Vision AI Limited公告股東會召開事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-08-25-1743-1v16qg","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-08-25","time":"17:43:30","subject":"說明暫未認列第二季美國地區權利金收入之緣由","clause":"第51款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-08-25 17:43，「說明暫未認列第二季美國地區權利金收入之緣由」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-08-25-1738-9acjsf","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"17:38:45","subject":"依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第四款規定公告","clause":"第22款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-08-25 17:38，「依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第四款規定公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-08-25-1738-37n2dy","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"17:38:14","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-08-25 17:38，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-08-25-1731-yclg0e","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"17:31:32","subject":"公告本公司因會計師事務所內部輪調更換會計師","clause":"第7款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-08-25 17:31，「公告本公司因會計師事務所內部輪調更換會計師」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6621-2026-08-25-1658-1asqitd","company_id":"6621","company":"華宇藥","market":"興櫃","industry":"生技醫療","date":"2026-08-25","time":"16:58:51","subject":"公告本公司「同伴動物的纖維蛋白／纖維蛋白原降解產物偵測方法」取得中華民國經濟部智慧財產局專利核准審定書","clause":"第44款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：華宇藥（6621），2026-08-25 16:58，「公告本公司「同伴動物的纖維蛋白／纖維蛋白原降解產物偵測方法」取得中華民國經濟部智慧財產局專利核准審定書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2026-08-25-1618-g0mtjm","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"16:18:31","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告董事會通過各項議案","clause":"第53款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2026-08-25 16:18，「代重要子公司合富（中國）醫療科技股份有限公司公告董事會通過各項議案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2026-08-25-1618-xniiq7","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"16:18:01","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告召開2026年半年度業績說明會","clause":"第12款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2026-08-25 16:18，「代重要子公司合富（中國）醫療科技股份有限公司公告召開2026年半年度業績說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2026-08-25-1604-ilx51r","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2026-08-25","time":"16:04:33","subject":"本公司受邀參加先探投資週刊舉辦之「2026年生技投資論壇」","clause":"第30款","fact_date":"2026-09-03","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2026-08-25 16:04，「本公司受邀參加先探投資週刊舉辦之「2026年生技投資論壇」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-08-25-1551-1vbcs4u","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-08-25","time":"15:51:16","subject":"本公司民國115年度第二季合併財務報告業經董事會決議通過","clause":"第31款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-08-25 15:51，「本公司民國115年度第二季合併財務報告業經董事會決議通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4194-2026-08-25-1359-161h329","company_id":"4194","company":"禾生技","market":"興櫃","industry":"生技醫療","date":"2026-08-25","time":"13:59:29","subject":"本公司115年現金增資認股基準日等相關事宜","clause":"第9款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：禾生技（4194），2026-08-25 13:59，「本公司115年現金增資認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2026-08-25-1332-1v19gdp","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2026-08-25","time":"13:32:14","subject":"本公司Pidnarulex(CX-5461)單劑使用於具DNA修復缺陷且多線治療後無效的晚期實體腫瘤Phase 1b族群擴增人體臨床試驗已完成收案，進入數據分析階段，預計2027年第一季完成CSR。","clause":"第53款","fact_date":"2026-08-25","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2026-08-25 13:32，「本公司Pidnarulex(CX-5461)單劑使用於具DNA修復缺陷且多線治療後無效的晚期實體腫瘤Phase 1b族群」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-08-25-0647-fv8q4k","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-08-25","time":"06:47:23","subject":"代重要子公司Belite Bio, Inc公告將於115年9月2日舉辦線上商業日(Virtual Commercial Day)","clause":"第44款","fact_date":"2026-09-02","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-08-25 06:47，「代重要子公司Belite Bio, Inc公告將於115年9月2日舉辦線上商業日(Virtual Commercial 」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}